EVEREST MED (01952.HK) Stock Community - Hot Topic Discussions

Quote List Quote List

Event Tracking

Nov20

Everbright Bio Launches Global Phase I Trial for EVM14

04:22

Nov13

Everbright Bio Displays Core Product Nafaquan at ASN Kidney Week

10:51

Oct30

Everbright Bio-Medicines Acquires Exclusive License From Visara For Clinical Development

03:54

Oct29

Cloud Top 耀 Secures Exclusive License for VIS-101, Entering Ophthalmology Market

23:12

Oct22

Innovent Biologics Holds Strategic Investor Meeting

00:07

Oct14

Yutong Xinyao's EVM14 Injection Enters First Patient in Global Phase I Clinical Trial

05:16

Schedules & Filings

Schedules

Filings

Aug28

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 244.15 M, Net Income -136.7 M, EPS -0.4201

Mar25

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 215.52 M, Net Income -217.54 M, EPS -0.6706

Aug27

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 161.99 M, Net Income -339.77 M, EPS -1.0593

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change